Topical Ketotifen 0.25% for Secondary Vestibulodynia

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

The Center for Vulvovaginal Disorders - Washington, DC, Washington D.C., District of Columbia

The Center for Vulvovaginal Disorders, Tampa, Florida

The Center for Vulvovaginal Disorders - New York, New York, New York